Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.
Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.
复制标题
DOI：
10.1155/2016/5706814
复制
发表时间：
2016
影响因子：
4.1
通讯作者：
Gao QL
中科院分区：
文献类型：
--
作者：
Han L;Shang YM;Song YP;Gao QL
使用自体的腺嘌呤诱导的杀伤（CIK）细胞的抑制性细胞疗法（ACT）是转移癌的有希望的治疗。在这项研究中，我们研究了RetroNectin对胰腺癌患者CIK细胞增殖，表型改变，细胞因子分泌和细胞毒活性的影响。此外，我们使用自体RetroNectin激活的CIK细胞（R-CIK细胞）单独或与化疗联合治疗13例转移性或局部晚期胰腺癌患者。与仅CD 3激活的CIK细胞（OKT-CIK细胞）相比，R-CIK细胞表现出更强、更快的增殖能力，自发凋亡率更低。此外，这种能力在IL-2从培养系统中撤出后继续存在。R-CIK细胞分泌的IL-2水平高于OKT-CIK细胞，而IL-4和IL-5水平低于OKT-CIK细胞。OKT-CIK和R-CIK细胞对淋巴瘤细胞系K562的杀伤能力无差异。在接受auto-R-CIK细胞输注治疗的患者中，总体客观缓解率为23.1%。首次R-CIK细胞输注后的中位生存时间（mOS）为10.57个月; 1年生存率为38.5%。无严重毒性与R-CIK细胞输注相关。总之，RetroNectin可以增强CIK细胞的抗肿瘤活性：其用于治疗胰腺癌是安全的。
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.